Results 181 to 190 of about 145,113 (281)

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

British Journal of Haematology, EarlyView.
Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli, Annamaria Giordano, Sara Martinelli, Caterina Patti, Paolo Sportoletti, Alessandro Sanna, Nilla Maschio, Rossella Riccioni, Clara Virginia Viganò, Agostino Tafuri, Alfonso Piciocchi, Paola Fazi, Stefano Luminari, Andrés J. M. Ferreri, Guido Gini, Paolo Ghia, Antonio Cuneo   +25 more
wiley   +1 more source

Benign Keratoses With Inverted Follicular Keratosis‐Like Features in a Patient Receiving Ripretinib: A Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Inverted follicular keratosis (IFK) is a rare benign neoplasm of the follicular infundibulum and typically presents as a solitary, nonpigmented verrucous papule on the head and neck of older males and can mimic viral warts, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC). We report a case of multiple benign keratoses with IFK‐like
Elsayed Ibrahim, Saira George, Peter N. Kundert, Benjamin H. Perkins, Jonathan L. Curry, Phyu P. Aung   +5 more
wiley   +1 more source

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review). [PDF]

Int J Oncol
Wan M, Wang X, Luo B, Hong H, Zhu Y, Lin T.   +5 more
europepmc   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology. [PDF]

Blood Adv
Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Savage KJ, Villa D, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Scott DW.   +18 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Porphyromonas gingivalis-derived lipopolysaccharide confers chemotherapy resistance and migratory ability on oral cancer cells by activating toll-like receptor 4 signaling pathway. [PDF]

Mol Biol Rep
Yamashita Y, Shigeishi H, Yokoyama S, Uetsuki R, Shiba F, Ono S, Ohta K, Aikawa T.   +7 more
europepmc   +1 more source

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

The FEBS Journal, EarlyView.
Autophagy is a cellular degradation process involved in, for example, immune responses to pathogens and neurodegeneration. To identify modulators of autophagy, we developed a microscopy‐based screening assay and identified previously unknown autophagy‐modulating activities in known drugs and natural products from myxobacteria and fungi.
Janine Fichtner, Yan Yan Beer, H. G. Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Rolf Müller, Manfred Wirth, Eeva‐Liisa Eskelinen, Ingo Schmitz   +13 more
wiley   +1 more source

Integrative bioinformatics, single-cell and experimental evidence for a BPA-m6A-apoptosis axis in granulosa cell dysfunction in polycystic ovary syndrome. [PDF]

J Ovarian Res
Zhang Y, Lin Y, Xiong X, Chen X, Liu X, Huang H.   +5 more
europepmc   +1 more source

BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source